While GLYX-13 will likely be indicated for patients who failed to benefit from conventional antidepressants first, the company is also beginning to study an oral version of the drug.
Naurex said the main side effects in a Phase IIa study of its GLYX-13 compound with 116 people with depression were headache and sleepiness, similar to the effects of a placebo saline injection.